Development of multidrug resistance (MDR) to conventional and newer generations of anticancer therapeutics is a significant challenge in cancer therapy. MDR is presented clinically as a consequence of many factors that include poor systemic drug delivery efficiency, short residence time, poor permeability in tumor mass and intracellular availability, as well as microenvironmental selection pressures that give rise to resistant phenotype. As such, our innovative strategy to overcome MDR is based on development of combinatorial designed nano-formulation libraries with encapsulated small interference RNA (against mdr-1 and mrp-1 efflux transporter and Bcl-2 and survivin anti-apoptotic genes) and cytotoxic therapeutic agents (paclitaxel and doxorubicin). Our preliminary studies show that this multimodal therapeutic approach has significant potential in the treatment of refractory tumors.
The specific aims of this project are: (1) to synthesize and characterize dextran-based macrostructures with fatty acids, thiol groups, poly(ethylene glycol) (PEG), and epidermal growth factor receptor (EGFR)- targeting peptide for combinatorial self-assembly in aqueous media into nanostructures that can encapsulate siRNA duplexes, paclitaxel, and doxorubicin;(2) high-throughput evaluation of cellular delivery and vesicular stability of siRNA duplexes and drugs, quantitative and qualitative gene silencing efficacy, cytotoxicity and apoptotic activity in wild-type (SK0V3) mdr-1 positive (SKOVSTR) human ovarian adenocarcinoma and wild- type (NIH-H69) and mrp-1 positive (NIH-H69AR) small cell lung adenocarcinoma cells;(3) selection of """"""""hits"""""""" for in vivo evaluation of tumor targeting efficacy, residence, biodistribution profiles, and evaluation of non- compartmental pharmacokinetics in SK0V3TR and NIH-H69AR tumor xenograft models after systemic administration;(4) further refinement of """"""""hits"""""""" and evaluation of in vivo gene silencing efficacy, tumor suppression, and inhibition of metastasis resistant tumor xenograft models after systemic administration of single and combination sIRNA/drug co-therapy;and (5) determination of acute safety profiles by measuring changes in body weight, blood cell counts, liver enzymes, and liver tissue histopathology with single and combination siRNA/drug co-therapy in resistant tumor models. The proposed clinically-translatable strategy holds tremendous promise in the treatment of refractory ovarian and small cell lung cancers, which continue to have very high mortality rates in the United States.

Public Health Relevance

Tumor multidrug resistance (MDR) is a serious challenge in clinical cancer therapy. A multimodal approach that enhances drug delivery efficiency as well as overcomes cellular resistance is necessary to successfully treat MDR in cancer patients. In this study, we will develop a novel class of biocompatible dextran-based polymeric nano-assembled structures for encapsulation and delivery of small interfering RNA that can silence specific genes in resistant cells. and cytotoxic drugs for maximum cell-kill effect.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-X (M1))
Program Officer
Grodzinski, Piotr
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northeastern University
Schools of Pharmacy
United States
Zip Code
Tang, Fan; Choy, Edwin; Tu, Chongqi et al. (2017) Therapeutic applications of histone deacetylase inhibitors in sarcoma. Cancer Treat Rev 59:33-45
Ahmad, Gulzar; El Sadda, Rana; Botchkina, Galina et al. (2017) Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth. Cancer Lett 406:71-80
Chen, Hua; Garbutt, Cassandra C; Spentzos, Dimitrios et al. (2017) Expression and Therapeutic Potential of SOX9 in Chordoma. Clin Cancer Res 23:5176-5186
Min, Li; Choy, Edwin; Tu, Chongqi et al. (2017) Application of metabolomics in sarcoma: From biomarkers to therapeutic targets. Crit Rev Oncol Hematol 116:1-10
Liu, Pei; Shen, Jacson K; Hornicek, Francis J et al. (2017) Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma. Sci Rep 7:1580
Liao, Yunfei; Chen, Lulu; Feng, Yong et al. (2017) Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget 8:30276-30287
Nascimento, Ana Vanessa; Singh, Amit; Bousbaa, Hassan et al. (2017) Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomater 47:71-80
Trivedi, Malav; Singh, Amit; Talekar, Meghna et al. (2017) MicroRNA-34a Encapsulated in Hyaluronic Acid Nanoparticles Induces Epigenetic Changes with Altered Mitochondrial Bioenergetics and Apoptosis in Non-Small-Cell Lung Cancer Cells. Sci Rep 7:3636
Liao, Yunfei; Sassi, Slim; Halvorsen, Stefan et al. (2017) Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. Sci Rep 7:43941
Duan, Zhenfeng; Gao, Yan; Shen, Jacson et al. (2017) miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo. Mol Oncol 11:151-166

Showing the most recent 10 out of 57 publications